765 related articles for article (PubMed ID: 18923523)
1. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.
Janoueix-Lerosey I; Lequin D; Brugières L; Ribeiro A; de Pontual L; Combaret V; Raynal V; Puisieux A; Schleiermacher G; Pierron G; Valteau-Couanet D; Frebourg T; Michon J; Lyonnet S; Amiel J; Delattre O
Nature; 2008 Oct; 455(7215):967-70. PubMed ID: 18923523
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic mutations of ALK kinase in neuroblastoma.
Chen Y; Takita J; Choi YL; Kato M; Ohira M; Sanada M; Wang L; Soda M; Kikuchi A; Igarashi T; Nakagawara A; Hayashi Y; Mano H; Ogawa S
Nature; 2008 Oct; 455(7215):971-4. PubMed ID: 18923524
[TBL] [Abstract][Full Text] [Related]
3. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
Passoni L; Longo L; Collini P; Coluccia AM; Bozzi F; Podda M; Gregorio A; Gambini C; Garaventa A; Pistoia V; Del Grosso F; Tonini GP; Cheng M; Gambacorti-Passerini C; Anichini A; Fossati-Bellani F; Di Nicola M; Luksch R
Cancer Res; 2009 Sep; 69(18):7338-46. PubMed ID: 19723661
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic mutations of ALK in neuroblastoma.
Ogawa S; Takita J; Sanada M; Hayashi Y
Cancer Sci; 2011 Feb; 102(2):302-8. PubMed ID: 21205076
[TBL] [Abstract][Full Text] [Related]
5. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
6. Identification of ALK as a major familial neuroblastoma predisposition gene.
Mossé YP; Laudenslager M; Longo L; Cole KA; Wood A; Attiyeh EF; Laquaglia MJ; Sennett R; Lynch JE; Perri P; Laureys G; Speleman F; Kim C; Hou C; Hakonarson H; Torkamani A; Schork NJ; Brodeur GM; Tonini GP; Rappaport E; Devoto M; Maris JM
Nature; 2008 Oct; 455(7215):930-5. PubMed ID: 18724359
[TBL] [Abstract][Full Text] [Related]
7. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
8. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
[TBL] [Abstract][Full Text] [Related]
9. Germline gain-of-function mutations of ALK disrupt central nervous system development.
de Pontual L; Kettaneh D; Gordon CT; Oufadem M; Boddaert N; Lees M; Balu L; Lachassinne E; Petros A; Mollet J; Wilson LC; Munnich A; Brugière L; Delattre O; Vekemans M; Etchevers H; Lyonnet S; Janoueix-Lerosey I; Amiel J
Hum Mutat; 2011 Mar; 32(3):272-6. PubMed ID: 21972109
[TBL] [Abstract][Full Text] [Related]
10. All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK.
Futami H; Sakai R
Cancer Lett; 2010 Nov; 297(2):220-5. PubMed ID: 20576349
[TBL] [Abstract][Full Text] [Related]
11. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.
Martinsson T; Eriksson T; Abrahamsson J; Caren H; Hansson M; Kogner P; Kamaraj S; Schönherr C; Weinmar J; Ruuth K; Palmer RH; Hallberg B
Cancer Res; 2011 Jan; 71(1):98-105. PubMed ID: 21059859
[TBL] [Abstract][Full Text] [Related]
12. In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)?
Mathivet T; Mazot P; Vigny M
Cell Signal; 2007 Dec; 19(12):2434-43. PubMed ID: 17904822
[TBL] [Abstract][Full Text] [Related]
13. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.
Mazot P; Cazes A; Boutterin MC; Figueiredo A; Raynal V; Combaret V; Hallberg B; Palmer RH; Delattre O; Janoueix-Lerosey I; Vigny M
Oncogene; 2011 Apr; 30(17):2017-25. PubMed ID: 21242967
[TBL] [Abstract][Full Text] [Related]
14. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.
Ogura T; Hiyama E; Kamei N; Kamimatsuse A; Ueda Y; Ogura K
J Pediatr Surg; 2012 Oct; 47(10):1789-96. PubMed ID: 23084186
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells.
Schönherr C; Yang HL; Vigny M; Palmer RH; Hallberg B
Oncogene; 2010 May; 29(19):2817-30. PubMed ID: 20190816
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma.
Bourdeaut F; Trochet D; Janoueix-Lerosey I; Ribeiro A; Deville A; Coz C; Michiels JF; Lyonnet S; Amiel J; Delattre O
Cancer Lett; 2005 Oct; 228(1-2):51-8. PubMed ID: 15949893
[TBL] [Abstract][Full Text] [Related]
17. Biological role of anaplastic lymphoma kinase in neuroblastoma.
Osajima-Hakomori Y; Miyake I; Ohira M; Nakagawara A; Nakagawa A; Sakai R
Am J Pathol; 2005 Jul; 167(1):213-22. PubMed ID: 15972965
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
19. Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma.
Cazes A; Louis-Brennetot C; Mazot P; Dingli F; Lombard B; Boeva V; Daveau R; Cappo J; Combaret V; Schleiermacher G; Jouannet S; Ferrand S; Pierron G; Barillot E; Loew D; Vigny M; Delattre O; Janoueix-Lerosey I
Cancer Res; 2013 Jan; 73(1):195-204. PubMed ID: 23139213
[TBL] [Abstract][Full Text] [Related]
20. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.
Okubo J; Takita J; Chen Y; Oki K; Nishimura R; Kato M; Sanada M; Hiwatari M; Hayashi Y; Igarashi T; Ogawa S
Oncogene; 2012 Nov; 31(44):4667-76. PubMed ID: 22249260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
